TSS
IMDX

Two Sigma Securities’s Insight Molecular Diagnostics IMDX Stock Holding History

Two Sigma Securities’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,215
Closed -$31.5K – 1991
2024
Q4 		$31.5K Buy
+13,215
New +$35.9K ﹤0.01% 1244
2023
Q3 		– Sell
-2,558
Closed -$11.8K – 3314
2023
Q2 		$11.8K Buy
2,558
+1,934
+310% +$9.74K ﹤0.01% 2573
2023
Q1 		$4.42K Sell
624
-107
-15% -$794 ﹤0.01% 2534
2022
Q4 		$4.69K Buy
+731
New +$8.06K ﹤0.01% 2458
2022
Q3 		– Sell
-1,061
Closed -$19K – 2947
2022
Q2 		$19K Buy
+1,061
New +$24.1K ﹤0.01% 1967

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIA
Wealthedge Investment Advisors New York $294M AUM 20.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Securities's IMDX Position: Q1 2025 in Review

Two Sigma Securities sold out of Insight Molecular Diagnostics (IMDX) in Q1 2025, closing a stake of 13,215 shares — an estimated $31.5K sold.

Two Sigma Securities first reported a position in IMDX in Q2 2022 and held it in 5 quarters. The position peaked at $31.5K in Q4 2024. 30 funds tracked by Wall St. Rank hold IMDX as of Q1 2025.

  • Two Sigma Securities reported no remaining Insight Molecular Diagnostics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 13,215 Insight Molecular Diagnostics shares in Q1 2025, an estimated $31.5K.
  • Two Sigma Securities first reported a position in Insight Molecular Diagnostics in Q2 2022 and held it in 5 quarters.
  • Two Sigma Securities's Insight Molecular Diagnostics position peaked at $31.5K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.